Olivia Keiser

Olivia Keiser

Auto-generated profile, based on publicly available information

Olivia Keiser

Institute of Global Health, University of Geneva, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
GCGary M. Clifford
Gary M. Clifford
Jerry PoleselJerry Polesel
Jerry Polesel
MRMartin Rickenbach
Martin Rickenbach
OSon behalf of the Swiss HIV Cohort Study
on behalf of the Swiss HIV Cohort Study
LMLuigino DAL MASO
Luigino DAL MASO
SFSilvia Franceschi
Silvia Franceschi
Background: Persons infected with human immunodeficiency virus (HIV) have an increased risk for several cancers, but the influences of behavioral risk factors, such as smoking and intravenous drug use, and highly active antiretroviral therapy (HAART) on cancer risk are not clear. Methods: Patient records were linked between the Swiss HIV Cohort Study and Swiss cantonal cancer registries. Observed and expected numbers of incident cancers were assessed in 7304 persons infected with HIV followed for 28 836 person-years. Relative risks for cancer compared with those for the general population were determined by estimating cancer registry–, sex-, age-, and period-standardized incidence ratios (SIRs). Results: Highly elevated SIRs were confirmed in persons infected with HIV for Kaposi sarcoma (KS) (SIR = 192, 95% confidence interval [CI] = 170 to 217) and non-Hodgkin lymphoma (SIR = 76.4, 95% CI = 66.5 to 87.4). Statistically significantly elevated SIRs were also observed for anal cancer (SIR = 33.4, 95% CI = 10.5 to 78.6); Hodgkin lymphoma (SIR = 17.3, 95% CI = 10.2 to 27.4); cancers of the cervix (SIR = 8.0, 95% CI = 2.9 to 17.4); liver (SIR = 7.0, 95% CI = 2.2 to 16.5); lip, mouth, and pharynx (SIR = 4.1, 95% CI = 2.1 to 7.4); trachea, lung, and bronchus (SIR = 3.2, 95% CI = 1.7 to 5.4); and skin, nonmelanomatous (SIR = 3.2, 95% CI = 2.2 to 4.5). In HAART users, SIRs for KS (SIR = 25.3, 95% CI = 10.8 to 50.1) and non-Hodgkin lymphoma (SIR = 24.2, 95% CI = 15.0 to 37.1) were lower than those for nonusers (KS SIR = 239, 95% CI = 211 to 270; non-Hodgkin lymphoma SIR = 99.3, 95% CI = 85.8 to 114). Among HAART users, however, the SIR (although not absolute numbers) for Hodgkin lymphoma (SIR = 36.2, 95% CI = 16.4 to 68.9) was comparable to that for KS and non-Hodgkin lymphoma. No clear impact of HAART on SIRs emerged for cervical cancer or non–acquired immunodeficiency syndrome-defining cancers. Cancers of the lung, lip, mouth, or pharynx were not observed among nonsmokers. Conclusion: In persons infected with HIV, HAART use may prevent most excess risk of KS and non-Hodgkin lymphoma, but not that of Hodgkin lymphoma and other non–acquired immunodeficiency syndrome-defining cancers. No cancers of the lip, mouth, pharynx, or lung were observed in nonsmokers.

9 April 2013 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
LJLeigh F. Johnson
Leigh F. Johnson
JMJoël Mossong
Joël Mossong
RDRob E. Dorrington
Rob E. Dorrington
MSMichael Schomaker
Michael Schomaker
CHChristopher J. Hoffmann
Christopher J. Hoffmann
FCfor the International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration
for the International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration
Leigh Johnson and colleagues estimate the life expectancies of HIV positive South African adults who are taking antiretroviral therapy by using information from 6 programmes between 2001 and 2010.

20 February 2014 in AIDS
Verified
Journal Article
Closed access
LTLyson Tenthani
Lyson Tenthani
AHAndreas D. Haas
Andreas D. Haas
HTHannock Tweya
Hannock Tweya
AJAndreas Jahn
Andreas Jahn
JOJoep J. van Oosterhout
Joep J. van Oosterhout
OKOlivia Keiser
Olivia Keiser
Objective: To explore the levels and determinants of loss to follow-up (LTF) under universal lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women (‘Option B+’) in Malawi. Design, setting, and participants: We examined retention in care, from the date of ART initiation up to 6 months, for women in the Option B+ program. We analysed nationwide facility-level data on women who started ART at 540 facilities (n = 21 939), as well as individual-level data on patients who started ART at 19 large facilities (n = 11 534). Results: Of the women who started ART under Option B+ (n = 21 939), 17% appeared to be lost to follow-up 6 months after ART initiation. Most losses occurred in the first 3 months of therapy. Option B+ patients who started therapy during pregnancy were five times more likely than women who started ART in WHO stage 3/4 or with a CD4+ cell count 350 cells/μl or less, to never return after their initial clinic visit [odds ratio (OR) 5.0, 95% confidence interval (CI) 4.2–6.1]. Option B+ patients who started therapy while breastfeeding were twice as likely to miss their first follow-up visit (OR 2.2, 95% CI 1.8–2.8). LTF was highest in pregnant Option B+ patients who began ART at large clinics on the day they were diagnosed with HIV. LTF varied considerably between facilities, ranging from 0 to 58%. Conclusion: Decreasing LTF will improve the effectiveness of the Option B+ approach. Tailored interventions, like community or family-based models of care could improve its effectiveness.

1 January 2005 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
MRMargalida Rotger
Margalida Rotger
SCSara Colombo
Sara Colombo
HFHansjakob Furrer
Hansjakob Furrer
GBGabriela Bleiber
Gabriela Bleiber
TBThierry Buclin
Thierry Buclin
ATAmalio Telenti
Amalio Telenti
Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Allele 516 G>T (Gln172His) is associated with diminished activity of this isoenzyme, and may lead to differences in drug exposure. We evaluated this allele as a pharmacogenetic marker of EFV and NVP pharmacokinetics and EFV toxicity in 167 participants receiving EFV and 59 receiving NVP recruited within the genetics project of the Swiss HIV Cohort Study. Drug concentrations were measured in plasma and in peripheral blood mononuclear cells (PBMCs) from the same sample. Neuropsychological toxicity of EFV (sleep disorders, mood disorders, fatigue) was assessed using a standardized questionnaire. CYP2B6 516TT was associated with greater plasma and intracellular exposure to EFV, and greater plasma exposure to NVP. Intracellular drug concentration, and CYP2B6 genotype were predictors of EFV neuropsychological toxicity. CYP2B6 genotyping may be useful to complement an individualization strategy based on plasma drug determinations to increase the safety and tolerability of EFV.

20 September 2012 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
CMCatrina Mugglin
Catrina Mugglin
JEJanne Estill
Janne Estill
GWGilles Wandeler
Gilles Wandeler
NBNicole Bender
Nicole Bender
MEMatthias Egger
Matthias Egger
FAfor IeDEA Southern Africa
for IeDEA Southern Africa
Objectives  To assess the proportion of patients lost to programme (died, lost to follow‐up, transferred out) between HIV diagnosis and start of antiretroviral therapy (ART) in sub‐Saharan Africa, and determine factors associated with loss to programme.Methods  Systematic review and meta‐analysis. We searched PubMed and EMBASE databases for studies in adults. Outcomes were the percentage of patients dying before starting ART, the percentage lost to follow‐up, the percentage with a CD4 cell count, the distribution of first CD4 counts and the percentage of eligible patients starting ART. Data were combined using random‐effects meta‐analysis.Results  Twenty‐nine studies from sub‐Saharan Africa including 148 912 patients were analysed. Six studies covered the whole period from HIV diagnosis to ART start. Meta‐analysis of these studies showed that of the 100 patients with a positive HIV test, 72 (95% CI 60–84) had a CD4 cell count measured, 40 (95% CI 26–55) were eligible for ART and 25 (95% CI 13–37) started ART. There was substantial heterogeneity between studies (P < 0.0001). Median CD4 cell count at presentation ranged from 154 to 274 cells/μl. Patients eligible for ART were less likely to become lost to programme (25%vs. 54%, P < 0.0001), but eligible patients were more likely to die (11%vs. 5%, P < 0.0001) than ineligible patients. Loss to programme was higher in men, in patients with low CD4 cell counts and low socio‐economic status and in recent time periods.Conclusions  Monitoring and care in the pre‐ART time period need improvement, with greater emphasis on patients not yet eligible for ART.

1 August 2010 in The Lancet
Verified
Journal Article
Closed access
MMMargaret May
Margaret May
ABAndrew Boulle
Andrew Boulle
SPSam Phiri
Sam Phiri
EMEugene Messou
Eugene Messou
LMLandon Myer
Landon Myer
MEMatthias Egger
Matthias Egger